Mark Malkin, MD
Neurology · Richmond, VANPI 1851344584
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Novocure Inc. accounts for 64.2% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $748, 2.5 times the $295 reported in 2019.
Across 24 payments — averaging $85.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novocure Inc.$1K
- Springworks Therapeutics, Inc.$246
- Monteris Medical Corporation$172
- UCB, Inc.$109
- Neurelis, Inc.$89
- GT Medical Technologies, Inc$61
- plus $61 from 1 others
Across 4 payments — averaging $15,128 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$61K
What the payments were for
- Food & beverage$2,062100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novocure Inc. | 14 | $1,325 |
| Springworks Therapeutics, Inc. | 2 | $246 |
| Monteris Medical Corporation | 4 | $172 |
| UCB, Inc. | 1 | $109 |
| Neurelis, Inc. | 1 | $89 |
| GT Medical Technologies, Inc | 1 | $61 |
| Medexus Pharma, Inc. | 1 | $61 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,062 in reported general payments places this provider in the 55th percentile of 474 neurology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Erlotinib Hcl | 11 | $19,677 |
| Ondansetron Hcl | 24 | $871 |
| Levetiracetam | 23 | $810 |
| Dexamethasone | 30 | $655 |
| Quetiapine Fumarate | 11 | $609 |
| Lamotrigine | 12 | $276 |
| Pantoprazole Sodium | 12 | $98 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $63 |
Paid to pharmacies, not to this prescriber.
Other neurology in Richmond
- Catherine HamRichmond$603K
- Daniel HardyRichmond$382K
- Myla GoldmanRichmond$132K
- Alan SchulmanRichmond$104K
- Warren FeltonRichmond$96K
- John WittmanRichmond$61K
- Matthew BoyceRichmond$56K
- Leslie CloudRichmond$46K
- Jonathan BekensteinRichmond$37K
- Jessica LehositRichmond$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.